PharmaFocus Today – Page 90 – media

New bispecific antibody company plans to go public in Hong Kong

In the biotechnology field, bispecific antibodies are becoming game-changing innovative therapeutics. On June 17, 2025, the Hong Kong IPO application of Innovent Biologics, a pioneer in the next-generation bispecific antibodies, was accepted and the prospectus was officially released. Founded in 2015, EpiMed Biopharma has been focused on developing bispecific antibodies using its proprietary bispecific antibody platform since its inception. Its strategic focus is on the field of T cell engagers, focusing on two major disease areas: tumors and autoimmune diseases. EpiMed has developed a proprietary technology platform designed to overcome the limitations of traditional bispecific antibody development: FIT-Ig platform: It has a unique linker-free, non-mutational and tetravalent bispecific antibody platform that can quickly generate bispecific antibody molecules while maintaining the biological function of each antibody domain, thereby achieving plug-and-play for multiple different targets. The FIT-Ig platform is the only bispecific antibody technology in the world that does not require any ...
- Source: drugdu
- 227
- June 23, 2025
Connoya sprints to become the “King of Chinese Self-immunity”

Recently, NEJM published the breakthrough data of Conoya’s BCMA/CD3 dual antibody CM336 in the treatment of refractory autoimmune hemolytic anemia (AIHA), with significant and lasting efficacy. This is not only a strong proof of its innovative strength, but also forms a synergy with the rapid commercialization of its trump card CM310, strongly supporting its sprint to become the king of autoimmune in China. BCMA/CD3 dual antibody autoimmune new blue ocean Bispecific antibody technology with T cell redirection as the core mechanism has made significant breakthroughs in the field of hematological tumors. Among them, BCMA/CD3 bispecific antibodies effectively guide cytotoxic T lymphocytes (CTL) to target and kill tumor cells through their unique dual antigen binding ability. Globally, two drugs, Teclistamab from Johnson & Johnson and Elranatamab from Pfizer, have been approved for relapsed and refractory multiple myeloma (RRMM). The former will land in the Chinese market in June 2024. Johnson & ...
- Source: drugdu
- 178
- June 23, 2025
Is It Worth Adding Chemo to ICI for NSCLC in Older Adults?

Immune checkpoint inhibitors (ICI) are a cornerstone of non-small cell lung cancer (NSCLC) treatment, but it’s not clear whether adding chemotherapy to ICI — a common practice with younger patients with NSCLC — helps older ones. No randomized trial has directly compared stand-alone ICI with chemoimmunotherapy in geriatric patients with NSCLC. Without strong data supporting the combined approach, oncologists may stay away from offering chemoimmunotherapy to older patients, especially to those with multiple comorbidities, given concerns about increased toxicity. To address the evidence gap, investigators linked Medicare and Surveillance, Epidemiology, and End Results data to compare outcomes between 14,249 older patients with NSCLC who received ICI alone (pembrolizumab or nivolumab) and 3432 treated with ICI and platinum doublet chemotherapy. Patients were aged 74 years, on average, and at least 66 years. The median follow-up duration was 211 days. The team weighed the risks and benefits of chemoimmunotherapy vs stand-alone ...
- Source: drugdu
- 127
- June 23, 2025
The World’s Only Twice-A-Year Shot to Prevent HIV Could Stop Transmission — if People Can Get It

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option. While a vaccine to prevent HIV still is needed, some experts say the shot made by Gilead Sciences — a drug called lenacapavir — could be the next best thing. It nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take. “This really has the possibility of ending HIV transmission,” said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research. Condoms help guard against HIV infection if used properly but what’s called PrEP — regularly using preventive medicines such as the daily pills or a different shot ...
- Source: drugdu
- 194
- June 23, 2025
Are Pre-Workout Powders Overloading the Heart?

Pre-workout supplements are gaining popularity in Brazil because of their promising effects, including increased focus, energy, endurance, enhanced performance, and reduced muscle fatigue. A growing number of brands are now available in specialty stores, pharmacies, and supermarkets. However, with so many options in the market, are consumers aware of the risks and product components, and do these products benefit physical performance? Typically sold in powdered soluble form, but also available as capsules, gummies, gels, or ready-to-drink liquids, pre-workout supplements combine various substances, such as caffeine, beta-alanine, arginine, taurine, and creatine, with formulas that vary by brand. “Pre-workout [supplements] usually have a combination of multiple elements, such as vitamins, proteins and amino acids, but only a very small portion actually have any effect with proven scientific evidence on sports performance,” said Cristiano Barcellos, PhD, director of the Department of Sports and Exercise Endocrinology at the Brazilian Society of Endocrinology and Metabolism. ...
- Source: drugdu
- 182
- June 20, 2025
Braces Top Best Therapies For Knee Arthritis

By Dennis Thompson HealthDay ReporterWEDNESDAY, June 18, 2025 (HealthDay News) — Throbbing, swollen knees hobble many seniors, but there are many solid means of treating knee arthritis that don’t involve meds, a new evidence review says. Knee braces, water therapy and exercise all effectively ease the ache of wear-and-tear knee arthritis, researchers reported today in the journal PLOS One. “They reduce pain and improve mobility without the gastrointestinal or cardiovascular risks linked to common pain medications,” wrote the research team led by senior researcher Yuan Luo of the First People’s Hospital of Neijiang in China. “Patients and clinicians should prioritize these evidence-based options,” researchers concluded. More than 10% of people older than 60 have knee arthritis, researchers said in background notes. That makes simple, cheap treatments a must, especially if they come without the side effects associated with many drugs. For the study, researchers pooled data from 139 clinical trials ...
- Source: drugdu
- 176
- June 20, 2025
The ‘Five Golden Flowers of the New Era’ Bloom, Large Funds Accelerate to Grab the Beach of Xiangjiang

Recently, the medical, technology, consumer, dividend, and financial sectors in the Hong Kong stock market have risen, and the “five golden flowers” continue to bloom. It is worth noting that the Hang Seng Shanghai Shenzhen Hong Kong Stock Connect AH Stock Premium Index recently hit a nearly five-year low, reflecting a significant narrowing of the discount between H-shares and A-shares. Why have the above sectors performed well recently? What is the condition of the “Five Golden Flowers” in the Hong Kong stock market? Is it a return of value or a game of funds behind it? Will the future market have sustainability? Around these issues, reporters from China Securities Journal interviewed multiple institutions. Our reporter Wang Xueqing Funding brings out ‘five golden flowers’ According to Wind data, as of June 17th, the cumulative net purchase amount of Hong Kong stocks by southbound funds since the beginning of this year ...
- Source: drugdu
- 182
- June 20, 2025
Adhere to the positioning of “hard technology” and pave the way for high-quality development on the Science and Technology Innovation Board

As of June 19th, the “Eight Measures for Deepening the Reform of the Science and Technology Innovation Board to Serve Technological Innovation and the Development of New Quality Productivity” (hereinafter referred to as the “Eight Measures for the Science and Technology Innovation Board”) has been implemented for one year. Following the reform path indicated by the “Eight Measures of the Science and Technology Innovation Board”, the board further highlights its “hard technology” positioning, and the IPO acceptance and review continue to release positive signals supporting the listing of high-quality “hard technology” enterprises. Dong Zhongyun, Chief Economist of AVIC Securities, told Securities Daily reporters that the implementation of the “Eight Measures for Science and Technology Innovation Board” has a significant impact on companies listed on the board: improving the financing environment and promoting more qualified technology innovation enterprises to go public smoothly; The inclusiveness of policies enables enterprises to focus more ...
- Source: drugdu
- 207
- June 20, 2025
Novo Nordisk and Ali Health launch strategic cooperation to promote digital upgrade of chronic disease management

China Securities Journal China Securities Network News (Reporter Fu Suying) Novo NordiskNovo Nordisk and Ali Health recently announced a strategic partnership. The two parties will rely on Novo Nordisk ‘s more than 100 years of professional experience and innovative treatment plans in the field of chronic diseases, as well as Ali Health ‘s innovative business model in the field of Internet medical care, to jointly create a one-stop weight management knowledge and service area to help the public understand healthy weight standards, master weight management methods, manage weight scientifically, and assist in one-stop diagnosis and treatment of diabetes and digital transformation and upgrading of chronic disease management. It is reported that the one-stop weight management knowledge and service zone jointly created by Ali Health and Novo Nordisk will deeply integrate the advantages of both parties to provide patients with a smart medical solution that integrates disease knowledge popularization, healthy weight ...
- Source: drugdu
- 266
- June 20, 2025
New psoriasis drug ASC50 completes first trial dosing in the U.S.

According to CSI Smart Finance , Ascletis Pharmaceuticals-B (01672) announced in the morning of June 18 that the board of directors announced that the first batch of healthy subjects have been dosed in the randomized, double-blind, placebo-controlled Phase I clinical trial of ASC50 in the United States. The trial aims to evaluate the safety, tolerability and preliminary efficacy of ASC50 in the treatment of psoriasis (NCT07024602). ASC50 is an oral small molecule interleukin-17 (IL-17) targeted inhibitor independently developed by Ascletis. IL-17 has been fully biologically validated in various autoimmune and inflammatory diseases such as psoriasis and has mature commercial value. Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, said: “We are pleased to announce that the first patient has been dosed in the clinical trial of ASC50 for the treatment of psoriasis ahead of schedule, starting the clinical development of this drug candidate. We look forward to obtaining the ...
- Source: drugdu
- 169
- June 20, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.